# HAIMA THERAPEUTICS, LLC: Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | HAIMA THERAPEUTICS, LLC |
| Location | CLEVELAND, OH |
| Project | Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management |
| Project number | 1SB1HL184353-01 |
| Mechanism | SB1 |
| Institute | National Heart Lung and Blood Institute |
| Award | $499,999 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-18 to 2027-08-31 |
| UEI | JKZPL4NA9V21 |

## Why this score
- Award of $400K or more.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11313383). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.